Research Triangle Park News
New Partnership Announced at RTP Between Biogen Idec and Eisai
December 12, 2012 (Research Triangle Park, N.C.) – A new, strategic alliance between RTP companies Biogen Idec and Eisai Inc will help ramp up the manufacturing capabilities of each companies’ central-North Carolina operations. Biogen will begin leasing a portion of the Eisai manufacturing facility to produce oral solid dose products for both companies. Eisai will be providing vial-filling and packing services for products produced by Biogen. Upon fulfillment of the 10-year lease agreement, Biogen Idec has the option to the purchase the Eisai oral solid dose facility.
“We view our supply chain as a lifeline to patients, designed to deliver quality therapies wherever and whenever they are needed,” said John G. Cox, executive vice president of Pharmaceutical Operations and Technology, for Biogen Idec. “This innovative capacity-sharing relationship with Eisai fits strategically in our global drug supply network, particularly as we advance our oral therapeutics.”
In early 2013, about 50 Eisai employees are expected to being working for Biogen Idec. This transfer will build upon Biogen Idec’s workforce at Research Triangle Park, which reached over 1,000 employees in 2012. Currently, Eisai employs around 225 employees in RTP.
"We look forward to collaborating with Biogen Idec to continue the proud history of drug manufacturing excellence here at our RTP site," said Lou Arp, general manager of the Eisai RTP site and president of Global Oncology Manufacturing, for Eisai Inc. "Our alliance will enable both companies to focus on respective areas of expertise while continuing to deliver high-quality and innovative products to patients. Moreover, employees will benefit by working in a highly collaborative environment that offers opportunities to further cultivate their careers.”
Both companies have maintained manufacturing facilities in RTP since the mid-1990s. “This alliance underscores the Triangle region’s reputation as a globally competitive location for life sciences,” said Bob Geolas, president and CEO of the Research Triangle Foundation. “In addition, it’s an illustration of the type of collaboration we encourage and foresee becoming more commonplace as the Park moves forward with its new Master Plan.”
About Biogen Idec
Innovative discoveries in science and medicine have been the backbone of Biogen Idec being founded in 1978. The company develops of patents, and creates therapies used in the treatment of hemophilia, autoimmune disorders, and neurodegenerative diseases. For more information about the company, please visit www.biogenidec.com
About Eisai Inc.
Established in 1995, Eisai focuses on neurology and oncology, and is a fully integrated pharmaceutical company. Eisai, Inc. is the U.S. operation of Eisai, Co., Ltd, a research-based human health care company that develops, markets and discovers products across the globe. North Carolina is home to both R&D and manufacturing facilities. For more information, please visit www.eisai.com/us.